



BioSpect

the business of BI

24 years of leveraging the business of Bio
www.biospectrumindia.com

Qure.ai partners with Microsoft to increase access to lung cancer detection and management suite in US

19 November 2025 | News

Accelerating early detection, reducing clinician burden, and enhancing patient outcomes



Mumbai-based startup Qure.ai has announced its collaboration with Microsoft. Qure.ai will onboard its end-to-end lung cancer detection, measurement and management suite of artificial intelligence (AI)-powered solutions onto the Precision Imaging Network.

This will streamline deployment of Qure.ai solutions to hospitals and health systems across the USA, driving digital healthcare transformation, improved tech integrations and ultimately enhance quality of patient care.

The Qure.ai suite of lung cancer algorithms are built from Large Language Models (LLMs) and Agentic AI, the very latest forms of artificial intelligence. Qure.ai augments clinical workflows between radiologists, pulmonologists, interventionalists and thoracic surgery teams, to accelerate the patient pathway from early detection to diagnosis and treatment.

It aims to answer the biggest cancer challenge in the US today, with lung cancer responsible for more deaths in the US than colon, breast and prostate cancers combined.

The Qure.ai FDA-cleared lung cancer solutions can be deployed as individual products, or collectively as a suite for a unified and cohesive workflow.